| First Author | Yang L | Year | 2022 |
| Journal | Elife | Volume | 11 |
| PubMed ID | 36458816 | Mgi Jnum | J:332129 |
| Mgi Id | MGI:7410613 | Doi | 10.7554/eLife.79811 |
| Citation | Yang L, et al. (2022) VPS9D1-AS1 overexpression amplifies intratumoral TGF-beta signaling and promotes tumor cell escape from CD8(+) T cell killing in colorectal cancer. Elife 11 |
| abstractText | Efficacy of immunotherapy is limited in patients with colorectal cancer (CRC) because high expression of tumor-derived transforming growth factor (TGF)-beta pathway molecules and interferon (IFN)-stimulated genes (ISGs) promotes tumor immune evasion. Here, we identified a long noncoding RNA (lncRNA), VPS9D1-AS1, which was located in ribosomes and amplified TGF-beta signaling and ISG expression. We show that high expression of VPS9D1-AS1 was negatively associated with T lymphocyte infiltration in two independent cohorts of CRC. VPS9D1-AS1 served as a scaffolding lncRNA by binding with ribosome protein S3 (RPS3) to increase the translation of TGF-beta, TGFBR1, and SMAD1/5/9. VPS9D1-AS1 knockout downregulated OAS1, an ISG gene, which further reduced IFNAR1 levels in tumor cells. Conversely, tumor cells overexpressing VPS9D1-AS1 were resistant to CD8(+) T cell killing and lowered IFNAR1 expression in CD8(+) T cells. In a conditional overexpression mouse model, VPS9D1-AS1 enhanced tumorigenesis and suppressed the infiltration of CD8(+) T cells. Treating tumor-bearing mice with antisense oligonucleotide drugs targeting VPS9D1-AS1 significantly suppressed tumor growth. Our findings indicate that the tumor-derived VPS9D1-AS1/TGF-beta/ISG signaling cascade promotes tumor growth and enhances immune evasion and may thus serve as a potential therapeutic target for CRC. |
